Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to support a Phase 1 clinical study of the Company’s lead program PRN-001-01 (tezampanel), a novel modulator of glutaminergic signaling designed to treat patients seeking to recover from opioid addiction and associated conditions.
Lead Product(s): Tezampanel
Therapeutic Area: Psychiatry/Psychology Product Name: PRN-001-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Accelerator Life Science Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 01, 2024
Details:
The grant supports development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel has demonstrated positive results in a variety of preclinical models of seizure disorder in clinical studies.
Lead Product(s): Tezampanel
Therapeutic Area: Psychiatry/Psychology Product Name: LY-293,558
Highest Development Status: N/AProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 17, 2020